Expert Perspectives on the Utility of Real-World Data in the Management of Plaque Psoriasis : Episode 11
Long Term Efficacy And Safety Data: IL-23 Inhibitors in Patients with Moderate to Severe Plaque Psoriasis
Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss year long term efficacy and safety data regarding the use of IL-23 inhibitors in patients with moderate to severe plaque psoriasis.
EP: 1.Plaque Psoriasis: Current Expansion of the Therapeutic Landscape
EP: 2.Shifting Treatment Approaches to Plaque Psoriasis
EP: 3.Current Role of Topical Therapy for Plaque Psoriasis Treatment
EP: 4.Spectrum of Disease and Current Treatment Options for Plaque Psoriasis
EP: 5.Plaque Psoriasis: Escalating Treatment
EP: 6.Communication With Patients About Plaque Psoriasis Treatment
EP: 7.IL-23 inhibitors for Plaque Psoriasis Treatment
EP: 8.Impact of Treatment Mode of Delivery on Patient Adherence and Plaque Psoriasis Treatment Selection
EP: 9.Long-Term Persistence of Biologic Treatment Options for Plaque Psoriasis
EP: 10.IL-23 Inhibitors and the Current Treatment Landscape for Plaque Psoriasis
Now Viewing
EP: 11.Long Term Efficacy And Safety Data: IL-23 Inhibitors in Patients with Moderate to Severe Plaque Psoriasis
EP: 12.BMI and Background Comorbidities that Impact Plaque Psoriasis Treatment
EP: 13.Plaque Psoriasis: Older Populations and Skin of Color
EP: 14.Looking Ahead at Clinical Trial Metrics for Plaque Psoriasis
EP: 15.Plaque Psoriasis: Future Therapeutic Pipeline
Related Videos
Related Content
